What is the appropriate starting dose of empagliflozin (Jardiance) for an adult with chronic kidney disease and proteinuria of 58 mg/g?

Starting Dose of Jardiance (Empagliflozin) for CKD with Proteinuria 58 mg/g

Start empagliflozin 10 mg once daily in the morning, taken with or without food, regardless of the proteinuria level of 58 mg/g. 1

Dosing Rationale

The FDA-approved starting dose for empagliflozin is 10 mg once daily for all approved indications, including CKD 1. This applies to your patient with proteinuria of 58 mg/g (equivalent to approximately 6.6 mg/mmol albumin-to-creatinine ratio), which represents moderately increased albuminuria.

Key Considerations Before Initiation:

• Assess renal function before starting empagliflozin 1
• Correct volume depletion if present before initiating therapy 1
• Verify eGFR ≥20 mL/min/1.73 m² - empagliflozin can be initiated down to this threshold for cardiorenal protection 2, 1

Dose Titration Strategy

For glycemic control only: The dose may be increased to 25 mg once daily in patients tolerating the 10 mg dose who need additional glucose lowering 1.

For cardiorenal protection: The 10 mg dose provides full cardiorenal benefits and dose escalation is not necessary. The landmark EMPA-KIDNEY trial, which demonstrated a 28% reduction in kidney disease progression or cardiovascular death, used empagliflozin 10 mg once daily 3.

Evidence Supporting This Approach

The EMPA-KIDNEY trial enrolled patients with eGFR 20-45 mL/min/1.73 m² OR eGFR 45-90 mL/min/1.73 m² with urine albumin-to-creatinine ratio ≥200 mg/g 3. Your patient's proteinuria of 58 mg/g falls below this threshold but still represents significant albuminuria warranting SGLT2 inhibitor therapy based on current guidelines 2.

Risk Stratification Context:

According to KDIGO classification 2:

• Proteinuria of 58 mg/g (approximately 6.6 mg/mmol) represents moderately increased albuminuria (3-30 mg/mmol range)
• This places the patient in at least moderate to high risk category depending on their eGFR
• SGLT2 inhibitors are strongly recommended across all CKD risk strata 2

Expected Effects and Monitoring

Anticipated Changes:

• Proteinuria reduction: Expect 18-40% reduction in albuminuria within 3-6 months 4. Higher urinary glucose excretion after initiation predicts greater proteinuria reduction 5
• Initial eGFR dip: A temporary 15-25% decrease in eGFR may occur in the first 1-3 months, which is hemodynamically mediated and not harmful 6. This should not prompt discontinuation
• Urinary glucose excretion: Approximately 64 grams/day with the 10 mg dose 1

Critical Monitoring Points:

• Do not stop empagliflozin for initial eGFR decline unless >30% drop within 3 months 6
• Continue therapy even if eGFR falls below 20 mL/min/1.73 m² once initiated (until dialysis) 2, 1
• Monitor for volume depletion, especially in patients ≥75 years 1

Safety Considerations

Contraindications:

• Patients on dialysis 1
• Hypersensitivity to empagliflozin 1

Common Pitfalls to Avoid:

1. Do not withhold due to the initial eGFR dip - this is expected and protective 6
2. Do not require diabetes for initiation - empagliflozin benefits CKD patients with or without diabetes 3
3. Implement "sick day" rules - temporarily stop during acute dehydrating illness 6
4. Monitor for genital mycotic infections - more common in uncircumcised men and those with prior infections 6

Long-term Benefits:

The long-term follow-up of EMPA-KIDNEY demonstrated that cardiorenal benefits persist for up to 12 months after discontinuation, with continued risk reduction during combined active and post-trial periods (HR 0.79,95% CI 0.72-0.87) 7.